A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.

Lei Wang, Jianjun Chang, Diana Varghese, Michael Dellinger, Subodh Kumar, Anne M. Best, Julio Ruiz, Richard Bruick, Samuel Peña-Llopis, Junjie Xu, David J. Babinski, Doug E. Frantz, Rolf A. Brekken, Amy M. Quinn, Anton Simeonov, Johnny Easmon, Elisabeth D. Martinez

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

The pharmacological inhibition of general transcriptional regulators has the potential to block growth through targeting multiple tumorigenic signalling pathways simultaneously. Here, using an innovative cell-based screen, we identify a structurally unique small molecule (named JIB-04) that specifically inhibits the activity of the Jumonji family of histone demethylases in vitro, in cancer cells, and in tumours in vivo. Unlike known inhibitors, JIB-04 is not a competitive inhibitor of α-ketoglutarate. In cancer, but not in patient-matched normal cells, JIB-04 alters a subset of transcriptional pathways and blocks viability. In mice, JIB-04 reduces tumour burden and prolongs survival. Importantly, we find that patients with breast tumours that overexpress Jumonji demethylases have significantly lower survival. Thus, JIB-04, a novel inhibitor of Jumonji demethylases in vitro and in vivo, constitutes a unique potential therapeutic and research tool against cancer, and validates the use of unbiased cellular screens to discover chemical modulators with disease relevance.

Original languageEnglish (US)
Article number2035
JournalNature Communications
Volume4
StatePublished - 2013

Fingerprint

Histone Demethylases
inhibitors
tumors
cancer
Molecules
Tumors
Growth
molecules
Neoplasms
regulators
cells
viability
breast
set theory
mice
modulators
Therapeutic Human Experimentation
Survival
Tumor Burden
Modulators

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)
  • Medicine(all)

Cite this

A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. / Wang, Lei; Chang, Jianjun; Varghese, Diana; Dellinger, Michael; Kumar, Subodh; Best, Anne M.; Ruiz, Julio; Bruick, Richard; Peña-Llopis, Samuel; Xu, Junjie; Babinski, David J.; Frantz, Doug E.; Brekken, Rolf A.; Quinn, Amy M.; Simeonov, Anton; Easmon, Johnny; Martinez, Elisabeth D.

In: Nature Communications, Vol. 4, 2035, 2013.

Research output: Contribution to journalArticle

Wang, L, Chang, J, Varghese, D, Dellinger, M, Kumar, S, Best, AM, Ruiz, J, Bruick, R, Peña-Llopis, S, Xu, J, Babinski, DJ, Frantz, DE, Brekken, RA, Quinn, AM, Simeonov, A, Easmon, J & Martinez, ED 2013, 'A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.', Nature Communications, vol. 4, 2035.
Wang, Lei ; Chang, Jianjun ; Varghese, Diana ; Dellinger, Michael ; Kumar, Subodh ; Best, Anne M. ; Ruiz, Julio ; Bruick, Richard ; Peña-Llopis, Samuel ; Xu, Junjie ; Babinski, David J. ; Frantz, Doug E. ; Brekken, Rolf A. ; Quinn, Amy M. ; Simeonov, Anton ; Easmon, Johnny ; Martinez, Elisabeth D. / A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. In: Nature Communications. 2013 ; Vol. 4.
@article{2caff6a061f241edb9ba207642bedbae,
title = "A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.",
abstract = "The pharmacological inhibition of general transcriptional regulators has the potential to block growth through targeting multiple tumorigenic signalling pathways simultaneously. Here, using an innovative cell-based screen, we identify a structurally unique small molecule (named JIB-04) that specifically inhibits the activity of the Jumonji family of histone demethylases in vitro, in cancer cells, and in tumours in vivo. Unlike known inhibitors, JIB-04 is not a competitive inhibitor of α-ketoglutarate. In cancer, but not in patient-matched normal cells, JIB-04 alters a subset of transcriptional pathways and blocks viability. In mice, JIB-04 reduces tumour burden and prolongs survival. Importantly, we find that patients with breast tumours that overexpress Jumonji demethylases have significantly lower survival. Thus, JIB-04, a novel inhibitor of Jumonji demethylases in vitro and in vivo, constitutes a unique potential therapeutic and research tool against cancer, and validates the use of unbiased cellular screens to discover chemical modulators with disease relevance.",
author = "Lei Wang and Jianjun Chang and Diana Varghese and Michael Dellinger and Subodh Kumar and Best, {Anne M.} and Julio Ruiz and Richard Bruick and Samuel Pe{\~n}a-Llopis and Junjie Xu and Babinski, {David J.} and Frantz, {Doug E.} and Brekken, {Rolf A.} and Quinn, {Amy M.} and Anton Simeonov and Johnny Easmon and Martinez, {Elisabeth D.}",
year = "2013",
language = "English (US)",
volume = "4",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.

AU - Wang, Lei

AU - Chang, Jianjun

AU - Varghese, Diana

AU - Dellinger, Michael

AU - Kumar, Subodh

AU - Best, Anne M.

AU - Ruiz, Julio

AU - Bruick, Richard

AU - Peña-Llopis, Samuel

AU - Xu, Junjie

AU - Babinski, David J.

AU - Frantz, Doug E.

AU - Brekken, Rolf A.

AU - Quinn, Amy M.

AU - Simeonov, Anton

AU - Easmon, Johnny

AU - Martinez, Elisabeth D.

PY - 2013

Y1 - 2013

N2 - The pharmacological inhibition of general transcriptional regulators has the potential to block growth through targeting multiple tumorigenic signalling pathways simultaneously. Here, using an innovative cell-based screen, we identify a structurally unique small molecule (named JIB-04) that specifically inhibits the activity of the Jumonji family of histone demethylases in vitro, in cancer cells, and in tumours in vivo. Unlike known inhibitors, JIB-04 is not a competitive inhibitor of α-ketoglutarate. In cancer, but not in patient-matched normal cells, JIB-04 alters a subset of transcriptional pathways and blocks viability. In mice, JIB-04 reduces tumour burden and prolongs survival. Importantly, we find that patients with breast tumours that overexpress Jumonji demethylases have significantly lower survival. Thus, JIB-04, a novel inhibitor of Jumonji demethylases in vitro and in vivo, constitutes a unique potential therapeutic and research tool against cancer, and validates the use of unbiased cellular screens to discover chemical modulators with disease relevance.

AB - The pharmacological inhibition of general transcriptional regulators has the potential to block growth through targeting multiple tumorigenic signalling pathways simultaneously. Here, using an innovative cell-based screen, we identify a structurally unique small molecule (named JIB-04) that specifically inhibits the activity of the Jumonji family of histone demethylases in vitro, in cancer cells, and in tumours in vivo. Unlike known inhibitors, JIB-04 is not a competitive inhibitor of α-ketoglutarate. In cancer, but not in patient-matched normal cells, JIB-04 alters a subset of transcriptional pathways and blocks viability. In mice, JIB-04 reduces tumour burden and prolongs survival. Importantly, we find that patients with breast tumours that overexpress Jumonji demethylases have significantly lower survival. Thus, JIB-04, a novel inhibitor of Jumonji demethylases in vitro and in vivo, constitutes a unique potential therapeutic and research tool against cancer, and validates the use of unbiased cellular screens to discover chemical modulators with disease relevance.

UR - http://www.scopus.com/inward/record.url?scp=84889595831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889595831&partnerID=8YFLogxK

M3 - Article

C2 - 23792809

AN - SCOPUS:84889595831

VL - 4

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 2035

ER -